Results 131 to 140 of about 99,547,245 (298)

SHP2 in Cancer: From Tumor Biology to Therapeutic Targeting

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA repair, angiogenesis ...
Maryam Jama   +2 more
wiley   +1 more source

High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome

open access: yesTherapeutic Advances in Medical Oncology
Background: CTLA-4 impedes the immune system’s antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents – ipilimumab and tremelimumab – both used together with anti-PD-1/PD-L1 agents.
Nithya Krishnamurthy   +9 more
doaj   +1 more source

Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy

open access: yesPrecision Radiation Oncology, EarlyView.
In this study, mean lung dose (MLD) and age were associated with an increased risk of treatment‐related pneumonitis in patients receiving concurrent chemoradiotherapy and immunotherapy, providing a reference for revising lung dose constraints. Abstract Objective Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively ...
Ying Lu   +9 more
wiley   +1 more source

Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis

open access: yesFrontiers in Endocrinology
ObjectiveImmune checkpoint inhibitors (ICIs) are revolutionary in oncology but may cause immune-related (IR) side effects, such as hypophysitis. Treatment with anti-PD-(L)1, anti-CTLA-4 or anti-CLTA-4/PD-1 may induce hypophysitis, but little is known ...
Stephanie van der Leij   +9 more
doaj   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada   +13 more
wiley   +1 more source

Endocytosis rates of CTLA-4 chimeras.

open access: yes, 2013
A. CHO cells expressing CTLA-4 chimeras were labeled at 4°C with anti-CTLA-4 to label surface CTLA-4. Cells were then warmed to 37°C to allow endocytosis for the times indicated.
Satdip Kaur (397530)   +2 more
core   +1 more source

Treg‐stromal cell axis in tissue repair and autoimmune diseases: Mechanisms and clinical translation

open access: yesRheumatology &Autoimmunity, EarlyView.
The Treg‐stromal cell axis as a central regulator of tissue repair and immune tolerance. Under physiological conditions, bidirectional communication between Tregs and stromal cells—mediated by cell‐surface molecular contacts, anti‐inflammatory cytokines, and extracellular vesicles—orchestrates inflammation resolution, immune tolerance, and complete ...
Peiyan Zhang   +2 more
wiley   +1 more source

Intersection of systemic lupus erythematosus and autoimmune thyroid disease: Shared pathophysiology, epidemiology, diagnosis, and management

open access: yesRheumatology &Autoimmunity, EarlyView.
A proposed mechanistic framework of systemic lupus erythematosus (SLE) and autoimmune thyroid disease (AITD) pathogenesis. In Stage 1, genetically susceptible individuals harbor risk variants within major histocompatibility complex (HLA) and non‐HLA loci that impair central and peripheral immune tolerance mechanisms within the thymic and peripheral ...
Elisa Elisa   +3 more
wiley   +1 more source

Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer

open access: yesEuropean Journal of Medical Research
Breast cancer (BC) has a high mortality rate and is one of the most common malignancies in the world. Initially, BC was considered non-immunogenic, but a paradigm shift occurred with the discovery of tumor-infiltrating lymphocytes (TILs) and regulatory T
Maryam Jama   +2 more
doaj   +1 more source

Generation and localisation of CTLA-4 chimeras.

open access: yes, 2013
A. C-terminal sequence alignments of selected mammalian CTLA-4 based on sequence data from Ensembl and in ref 12. B. Diagram of human CTLA-4 chimeras containing the extracellular and transmembrane domain of human CTLA-4 and the C-terminus of species ...
Satdip Kaur (397530)   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy